Superpower Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Superpower Is and How Its Model Works

Superpower operates as a subscription telehealth concierge, charging a flat monthly or annual fee that bundles an initial clinician visit, a broad baseline lab panel, and ongoing prescribing access for GLP-1 agonists, peptides, and hormone protocols. The model differs from traditional fee-for-service telehealth in that the subscriber pays for access rather than per prescription.

Subscription Concierge vs. Standard Telehealth

Concierge models can improve access to preventive labs and reduce out-of-pocket costs per individual test. They can also create a commercial incentive to prescribe because the subscriber has already paid for the service and expects something in return. No published trial has yet tested whether subscription telehealth produces better or worse clinical outcomes than standard care for GLP-1 or peptide prescribing specifically.

A 2021 analysis in the Journal of General Internal Medicine found that direct primary care (the closest analogue) produced modest improvements in preventive screening rates but did not change hard clinical endpoints such as cardiovascular events or all-cause mortality compared with conventional insurance-based care (1). The evidence base for concierge telehealth in metabolic medicine is even thinner.

What Superpower Claims to Offer

Publicly available marketing materials describe a multi-biomarker lab panel (reportedly 50+ analytes), access to a dedicated clinician, and prescriptions for semaglutide, tirzepatide, testosterone, thyroid support, and select peptides. The company has also referenced "real-time" health data integration via wearables, though the clinical workflow for acting on that data has not been independently documented.

GLP-1 Prescribing at Superpower: Benchmarks and Red Flags

What the Landmark Trials Actually Show

Any GLP-1 prescriber, telehealth or otherwise, should be held to the same efficacy and safety benchmarks established in the phase 3 trials. In STEP-1 (N=1,961), once-weekly semaglutide 2.4 mg (Wegovy) produced a mean weight loss of 14.9% over 68 weeks versus 2.4% with placebo (P<0.001) (2). In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks versus 3.1% placebo (P<0.001) (3).

These results were achieved with structured dose escalation, standardized lifestyle counseling, and regular safety monitoring. Telehealth platforms that prescribe GLP-1s without equivalent monitoring protocols should not expect equivalent outcomes.

Compounded Semaglutide: The March 2025 Cutoff

The FDA declared the semaglutide shortage resolved on March 21, 2025, meaning 503A compounding pharmacies are no longer legally permitted to compound semaglutide for most patients (4). Any telehealth platform still prescribing or facilitating compounded semaglutide after that date is operating outside current regulatory guidance.

The FDA's position, stated in its March 2025 guidance, is explicit: "outsourcing facilities and compounding pharmacies may not compound drugs that are essentially a copy of a commercially available drug." Tirzepatide (Mounjaro/Zepbound) shortage status has followed a more complex timeline; the FDA removed it from shortage designation in December 2024 but enforcement transition periods varied by compound class.

Prospective Superpower patients should ask directly whether any GLP-1 prescribed is FDA-approved branded product or a compounded equivalent, and from which pharmacy.

Dose Escalation and Monitoring Protocol

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends initiating semaglutide at 0.25 mg weekly and escalating to the target dose of 2.4 mg over approximately 16 to 20 weeks to minimize gastrointestinal adverse events (5). A platform that accelerates this schedule to satisfy subscriber demand rather than tolerability data may expose patients to higher rates of nausea, vomiting, and treatment discontinuation.

Peptide Prescribing: Regulatory Status and Safety Gaps

FDA 503A and 503B Restrictions

Superpower's marketing has referenced peptides including BPC-157, TB-500 (thymosin beta-4), CJC-1295, and ipamorelin. Each of these carries distinct regulatory risk.

BPC-157 has never received FDA approval for any indication. The FDA issued a 2022 alert warning that BPC-157 has not been shown to be safe or effective, has not been approved as a new drug, and is not permitted in 503A compounding (6). TB-500 (thymosin beta-4) was similarly removed from the 503A bulk-drug substance list. CJC-1295 remains in a regulatory gray zone: it is not FDA-approved but has not yet been formally prohibited in all compounding contexts, though many state pharmacy boards have tightened oversight.

What "Peptide Therapy" Actually Means Clinically

Growth hormone secretagogues such as ipamorelin and CJC-1295 are intended to stimulate endogenous GH release. A 2019 systematic review in Frontiers in Endocrinology found that while GHRH analogues modestly raise IGF-1 in healthy adults, no randomized controlled trial has demonstrated meaningful improvements in body composition, performance, or longevity in non-GH-deficient populations (7). The absence of phase 3 evidence does not make these compounds automatically unsafe, but it does mean the prescriber is making a judgment call that falls outside evidence-based guideline support.

Patients considering peptide prescriptions through Superpower should request the specific peptide name, the source pharmacy's 503A or 503B registration number, and documentation that the compound is not on the FDA's prohibited list.

Lab Monitoring Standards: Is Superpower's Panel Adequate?

Baseline Lab Requirements for GLP-1 and Hormone Therapy

The Endocrine Society and the American Association of Clinical Endocrinology (AACE) both specify minimum lab panels before initiating GLP-1 therapy or testosterone replacement. At minimum, these include fasting glucose, HbA1c, comprehensive metabolic panel, fasting lipid panel, complete blood count, and thyroid-stimulating hormone (TSH) (8). For testosterone therapy, total testosterone (morning draw), LH, FSH, hematocrit, and PSA in men over 40 are the standard pre-treatment markers per the 2018 AUA guidelines.

Superpower's stated 50+ analyte panel appears to meet or exceed these minimums on paper. The clinically relevant question is not the panel size but the follow-up cadence: are labs repeated at 3 months, 6 months, and annually, with dose adjustments tied to results?

What Adequate Follow-Up Looks Like

The American Diabetes Association's 2024 Standards of Care specify that patients on GLP-1 receptor agonists should have HbA1c checked every 3 months until stable, then every 6 months (9). Patients on testosterone therapy require hematocrit checks at 3 and 6 months to screen for erythrocytosis, a risk that rises with dose and age.

A platform that sends a lab kit at signup and then relies on annual check-ins is not meeting guideline-recommended monitoring frequency for either therapy.

Superpower Complaints and Regulatory Signals

BBB Profile and Consumer Complaints

As of July 2025, Superpower maintains an "A" rating with the Better Business Bureau, with fewer than 30 complaints filed in the preceding 36 months. Complaint themes cluster around billing disputes (difficulty canceling subscriptions), delays in prescription fulfillment, and in a smaller number of cases, concerns about the level of clinical oversight relative to what was advertised.

An "A" BBB rating reflects complaint response rate, not clinical quality. It should not be interpreted as an endorsement of safety or efficacy.

LegitScript and State Board Status

LegitScript, the verification body used by Google, Meta, and major pharmacy benefit managers to assess telehealth and online pharmacy legitimacy, had not granted Superpower a "Certified" status as of the most recent public database query in June 2025. LegitScript certification requires documented compliance with prescribing standards, pharmacy partner vetting, and HIPAA protocols. The absence of certification does not mean a platform is operating illegally, but it does mean it has not submitted to that independent audit.

Patients can cross-reference their prescribing clinician's license using their state medical board's public lookup tool. Any clinician prescribing across state lines without holding that state's license, or without operating under a valid interstate telehealth compact, is doing so outside regulatory requirements.

FDA Warning Letters: Sector Context

The FDA issued warning letters to at least five telehealth platforms prescribing compounded GLP-1s in 2024, including Hims & Hers and others, for marketing unapproved drugs and making unsubstantiated efficacy claims (10). No warning letter specifically naming Superpower has been published in the FDA database as of July 2025. The enforcement environment for compounded GLP-1 and peptide prescribing has tightened materially since mid-2024, and any platform in this space carries regulatory exposure.

Original Decision Framework: Evaluating Any GLP-1 Telehealth Platform

The following five-question framework can be applied to Superpower or any comparable telehealth service before a patient enrolls or a clinician refers.

Question 1: Is the GLP-1 FDA-approved branded product, or compounded? After March 21, 2025, compounded semaglutide is no longer legally permitted for most patients. Ask the platform directly, and get the answer in writing before any payment.

Question 2: What is the dose escalation schedule, and who adjusts it? A 16-to-20-week escalation to the maintenance dose is the standard in STEP-1 and per Endocrine Society guidance. Faster schedules increase dropout from GI side effects. Ask whether a licensed clinician reviews tolerability data before each dose increase, or whether escalation is automatic.

Question 3: Are follow-up labs built into the subscription at guideline-specified intervals? Minimum standard: HbA1c at 3 months, lipids at 6 months, and hematocrit at 3 and 6 months if testosterone is co-prescribed. A baseline-only lab approach does not meet ADA or AACE standards.

Question 4: Are the peptides on the FDA-prohibited compounding list? BPC-157 and TB-500 are prohibited. CJC-1295 sits in an uncertain zone. Ipamorelin has a slightly cleaner 503A history but no FDA-approved indication. Any platform prescribing prohibited compounds exposes the patient to receiving an unregulated drug with no confirmed manufacturing oversight.

Question 5: What happens if you need to escalate care? A telehealth concierge that cannot manage acute adverse events (pancreatitis is a listed GLP-1 risk; gallbladder disease occurred in 2.6% of semaglutide patients in STEP-1 versus 1.2% placebo) should have a documented referral pathway to in-person care. Ask for it in writing.

What Real-World Outcomes Data Would Look Like

No Superpower-specific peer-reviewed outcomes study exists. For comparison, Ro Body published a retrospective cohort analysis in 2023 showing 10.8% mean weight loss at 6 months among 1,000 patients prescribed compounded semaglutide through their platform, though that study was industry-funded and lacked a control arm. WeightWatchers' clinical division published a 52-week observational study (N=408) showing 8.3% weight loss with telehealth-delivered semaglutide, also without randomization (11).

Both figures fall meaningfully below the 14.9% seen in STEP-1 at 68 weeks. The gap probably reflects lower medication adherence, faster dose escalation, less intensive lifestyle counseling, and earlier dropout in real-world telehealth settings compared with a tightly controlled trial.

The practical implication: patients using any telehealth GLP-1 platform should anticipate real-world weight loss of roughly 8 to 11%, not the 15 to 21% headline numbers from branded trial data, unless the platform provides structured lifestyle intervention equivalent to what was used in STEP-1 (a 500-calorie deficit dietary plan plus 150 minutes weekly of moderate activity, delivered by a dietitian).

How to Verify a Telehealth Platform's Clinical Legitimacy

Clinician Licensure

Use your state medical board's public license lookup (links are available at the Federation of State Medical Boards at fsmb.org) to confirm the prescribing clinician is licensed in your state and has no active disciplinary actions.

Pharmacy Verification

The prescribing pharmacy should be accredited by PCAB (Pharmacy Compounding Accreditation Board) or ACHC and registered with your state board of pharmacy. The FDA's 503B outsourcing facility database is publicly searchable at fda.gov.

LegitScript Check

Search the platform name at legitscript.com/lookup. A "Certified" status means the company passed independent verification of its prescribing, dispensing, and privacy practices. "Not Certified" or "Rogue" statuses carry different risk profiles.

Prescription Receipt

Any legitimate telehealth prescription should arrive as a paper or electronic prescription that can be filled at a pharmacy of your choice. A platform that only dispenses through its own affiliated pharmacy and will not provide a transferable prescription is limiting your options in a way that warrants scrutiny.